Bonac Co., a Fukuoka-based startup with a focus on RNA therapeutics, has entered into an agreement with Toray to license for domestic use its drug candidate BNC-1021, an RNA for the treatment of idiopathic pulmonary fibrosis, to Toray who in turn has bought new Bonac shares.

Toray news release, January 6, 2016